Replaces Prod. #: BML-AP103
Potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) (IC50=9.5μM). Attenuates activation of ERK and p38 MAP kinase induced by LPS. Displays beneficial effects in LPS-induced endotoxic shock. Protects the heart from oxidative damage during reperfusion injury.
Product Details
| Alternative Name: | 4-HQN, 4-Quinazolinol |
| |
| Formula: | C8H6N2O |
| |
| MW: | 146.2 |
| |
| CAS: | 491-36-1 |
| |
| RTECS: | VA2300000 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Identity: | Determined by IR. |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in DMSO (50mg/ml) or methanol. |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | +4°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation: H. Kleine, et al.; Mol. Cell
32, 57 (2008),
Abstract;
Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice: B. Veres, et al.; J. Pharmacol. Exp. Ther.
310, 247 (2004),
Abstract;
Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system: R. Halmosi, et al.; Mol. Pharmacol.
59, 1497 (2001),
Abstract;
Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase: M. Banasik, et al.; J. Biol. Chem.
267, 1569 (1992),
Abstract;
